ReviewOncology letters2025
Molecular mechanisms and functions of guanylate-binding protein 2 in inflammation and cancer (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present review article aimed to summarize currently available research data on the roles and functions of human guanylate-binding protein 2 (hGBP2) and murine (m)GBP2 in cancer and inflammation. In addition, its structure, hydrolytic mechanisms and molecular regulatory mechanisms are discussed. hGBP2 and mGBP2 are strongly induced by IFN-γ through the IFN-sensitive response element and IFN-γ activation site sequences on their corresponding genes, whilst also being regulated by IFN-α, IFN-β and multiple STAT-IFN-regulatory factor complexes. In inflammation, hGBP2 primarily regulates activation of the NLR family pyrin domain-containing 3 and absent in melanoma 2 inflammasome pathways and therefore the induction of pyroptosis. By contrast, in cancer, hGBP2 serves a dual role, such that it can either promote cancer progression or suppress cancer development in a context-dependent manner. This leads to variations in the hGBP2 expression profile across different cancer types in addition to their corresponding prognostic outcomes. hGBP2 can also respond to paclitaxel, a notable anticancer drug. The present review aims to summarize the structural basis and regulatory mechanisms of hGBP2, elucidate the roles of both hGBP2 and mGBP2 in inflammation and cancer and propose prospective research directions to inform future fundamental investigations and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.